Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents. 2023

Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.

Mpox virus (formerly monkeypox virus [MPXV]) is a neglected zoonotic pathogen that caused a worldwide outbreak in May 2022. Given the lack of an established therapy, the development of an anti-MPXV strategy is of vital importance. To identify drug targets for the development of anti-MPXV agents, we screened a chemical library using an MPXV infection cell assay and found that gemcitabine, trifluridine, and mycophenolic acid (MPA) inhibited MPXV propagation. These compounds showed broad-spectrum anti-orthopoxvirus activities and presented lower 90% inhibitory concentrations (0.026 to 0.89 μM) than brincidofovir, an approved anti-smallpox agent. These three compounds have been suggested to target the postentry step to reduce the intracellular production of virions. Knockdown of IMP dehydrogenase (IMPDH), the rate-limiting enzyme of guanosine biosynthesis and a target of MPA, dramatically reduced MPXV DNA production. Moreover, supplementation with guanosine recovered the anti-MPXV effect of MPA, suggesting that IMPDH and its guanosine biosynthetic pathway regulate MPXV replication. By targeting IMPDH, we identified a series of compounds with stronger anti-MPXV activity than MPA. This evidence shows that IMPDH is a potential target for the development of anti-MPXV agents. IMPORTANCE Mpox is a zoonotic disease caused by infection with the mpox virus, and a worldwide outbreak occurred in May 2022. The smallpox vaccine has recently been approved for clinical use against mpox in the United States. Although brincidofovir and tecovirimat are drugs approved for the treatment of smallpox by the U.S. Food and Drug Administration, their efficacy against mpox has not been established. Moreover, these drugs may present negative side effects. Therefore, new anti-mpox virus agents are needed. This study revealed that gemcitabine, trifluridine, and mycophenolic acid inhibited mpox virus propagation and exhibited broad-spectrum anti-orthopoxvirus activities. We also suggested IMP dehydrogenase as a potential target for the development of anti-mpox virus agents. By targeting this molecule, we identified a series of compounds with stronger anti-mpox virus activity than mycophenolic acid.

UI MeSH Term Description Entries
D007168 IMP Dehydrogenase An enzyme that catalyzes the dehydrogenation of inosine 5'-phosphate to xanthosine 5'-phosphate in the presence of NAD. EC 1.1.1.205. Inosinic Acid Dehydrogenase,Inosine-5-Monophosphate Dehydrogenase,Acid Dehydrogenase, Inosinic,Dehydrogenase, IMP,Dehydrogenase, Inosine-5-Monophosphate,Dehydrogenase, Inosinic Acid,Inosine 5 Monophosphate Dehydrogenase
D008993 Monkeypox virus A species of ORTHOPOXVIRUS that is the etiological agent of MPOX (MONKEYPOX). MPXV Virus,Mpox Virus,Monkey Pox Virus,Monkeypoxvirus,MPXV Viruses,Monkey Pox Viruses,Monkeypox viruses,Monkeypoxviruses,Mpox Viruses,Virus, MPXV,Virus, Mpox,Viruses, MPXV,Viruses, Mpox
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D006151 Guanosine A purine nucleoside that has guanine linked by its N9 nitrogen to the C1 carbon of ribose. It is a component of ribonucleic acid and its nucleotides play important roles in metabolism. (From Dorland, 28th ed)
D014271 Trifluridine An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557) Trifluorothymidine,2'-deoxy-5-(trifluoromethyl)uridine,5-Trifluoromethyl-2'-deoxyuridine,TFT Ophtiole,Triflumann,Trifluoridine,Viromidin,Virophta,Viroptic,5 Trifluoromethyl 2' deoxyuridine

Related Publications

Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
January 1997, Antimicrobial agents and chemotherapy,
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
July 1996, Farmaco (Societa chimica italiana : 1989),
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
February 2020, Angewandte Chemie (International ed. in English),
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
September 2019, Cancers,
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
July 2004, The Journal of antimicrobial chemotherapy,
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
April 2012, Bioorganic & medicinal chemistry,
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
January 2010, Bioscience, biotechnology, and biochemistry,
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
March 2006, Toxicology,
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
February 2022, Antibiotics (Basel, Switzerland),
Takayuki Hishiki, and Takeshi Morita, and Daisuke Akazawa, and Hirofumi Ohashi, and Eun-Sil Park, and Michiyo Kataoka, and Junki Mifune, and Kaho Shionoya, and Kana Tsuchimoto, and Shinjiro Ojima, and Aa Haeruman Azam, and Shogo Nakajima, and Madoka Kawahara, and Tomoki Yoshikawa, and Masayuki Shimojima, and Kotaro Kiga, and Ken Maeda, and Tadaki Suzuki, and Hideki Ebihara, and Yoshimasa Takahashi, and Koichi Watashi
June 2008, Antiviral research,
Copied contents to your clipboard!